These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
701 related articles for article (PubMed ID: 26327240)
1. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240 [TBL] [Abstract][Full Text] [Related]
2. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. Chen CL; Tsukamoto H; Liu JC; Kashiwabara C; Feldman D; Sher L; Dooley S; French SW; Mishra L; Petrovic L; Jeong JH; Machida K J Clin Invest; 2013 Jul; 123(7):2832-49. PubMed ID: 23921128 [TBL] [Abstract][Full Text] [Related]
3. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178 [TBL] [Abstract][Full Text] [Related]
4. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525 [TBL] [Abstract][Full Text] [Related]
5. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma. Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246 [TBL] [Abstract][Full Text] [Related]
6. Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. Lu P; Sun H; Zhang L; Hou H; Zhang L; Zhao F; Ge C; Yao M; Wang T; Li J Mol Med; 2012 Sep; 18(1):1136-46. PubMed ID: 22714713 [TBL] [Abstract][Full Text] [Related]
8. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Jia Q; Zhang X; Deng T; Gao J Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193 [TBL] [Abstract][Full Text] [Related]
9. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214 [TBL] [Abstract][Full Text] [Related]
11. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. Chen L; Tian H; Li M; Ge C; Zhao F; Zhang L; Li H; Liu J; Wang T; Yao M; Li J Tumour Biol; 2016 May; 37(5):5951-61. PubMed ID: 26596832 [TBL] [Abstract][Full Text] [Related]
12. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338 [TBL] [Abstract][Full Text] [Related]
13. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. Wilson GS; Hu Z; Duan W; Tian A; Wang XM; McLeod D; Lam V; George J; Qiao L Stem Cells Dev; 2013 Oct; 22(19):2655-64. PubMed ID: 23638793 [TBL] [Abstract][Full Text] [Related]
17. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788 [TBL] [Abstract][Full Text] [Related]
18. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma. Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050 [TBL] [Abstract][Full Text] [Related]
19. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378 [TBL] [Abstract][Full Text] [Related]
20. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Jiang Y; He Y; Li H; Li HN; Zhang L; Hu W; Sun YM; Chen FL; Jin XM Gastric Cancer; 2012 Oct; 15(4):440-50. PubMed ID: 22395309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]